Hexarelin Research: What 313 Studies Show (2026) | RetatrutideCompare

Hexarelin — 313 studies indexed on PubMed. Potent ghrelin receptor agonist with cardioprotective signaling at the CD36 scavenger receptor. Half-life: ~70 minutes. FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Hexarelin?

There are approximately 313 studies indexed on PubMed that mention Hexarelin (Examorelin), based on a search last updated 2026-06-18.

Is Hexarelin FDA-approved?

FDA status: Not FDA-approved.

How does Hexarelin work?

Potent ghrelin receptor agonist with cardioprotective signaling at the CD36 scavenger receptor.

Reference facts

Also known as: Examorelin
Category: Growth Hormone & Ghrelin
Mechanism of action: Potent ghrelin receptor agonist with cardioprotective signaling at the CD36 scavenger receptor.
Targets: GHS-R1a, CD36
Indications under research or approved: Research (GH release, cardiac ischemia models)
Regulatory status (reference entry): Not FDA-approved
Half-life: ~70 minutes
Sequence notes: Hexapeptide H-His-D-2-MethylTrp-Ala-Trp-D-Phe-Lys-NH2.
Molecular weight (Da): 887
First reported: 1992

Primary References

Imbimbo et al., JCEM 1994 (Hexarelin GH)

Explore research articles about Hexarelin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.